Galera Therapeutics Analysis
Galera Therapeutics is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of Galera Therapeutics pink sheet analysis is to determine its intrinsic value, which is an estimate of what Galera Therapeutics is worth, separate from its market price. There are two main types of Galera Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Galera Therapeutics pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Galera |
Galera Pink Sheet Analysis Notes
About 36.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.91. Galera Therapeutics had not issued any dividends in recent years. Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. Galera Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 30 people.The quote for Galera Therapeutics is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To learn more about Galera Therapeutics call Mel MD at 610 725 1500 or check out https://www.galeratx.com.Galera Therapeutics Investment Alerts
| Galera Therapeutics is not yet fully synchronised with the market data | |
| Galera Therapeutics has some characteristics of a very speculative penny stock | |
| Galera Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (59.08 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Galera Therapeutics currently holds about 52.01 M in cash with (44.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.94. | |
| Roughly 36.0% of the company shares are held by company insiders |
Galera Therapeutics Upcoming and Recent Events
Earnings reports are used by Galera Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 13th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Galera Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 7.89 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Galera Therapeutics's market, we take the total number of its shares issued and multiply it by Galera Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Galera Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Galera Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Galera Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Galera Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Galera Therapeutics Outstanding Bonds
Galera Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Galera Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Galera bonds can be classified according to their maturity, which is the date when Galera Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Galera Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Balance Of Power Now
Balance Of PowerCheck stock momentum by analyzing Balance Of Power indicator and other technical ratios |
| All Next | Launch Module |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Consideration for investing in Galera Pink Sheet
If you are still planning to invest in Galera Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Galera Therapeutics' history and understand the potential risks before investing.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |